Stocks Health care NGNE
NASDAQ · Health careNeurogene Inc. (NGNE)
It posted a net loss of $119.2M. In fiscal 2025 capital spending exceeded operating cash flow by $78.4M. At September 30, 2026 it held $78.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Neurogene Inc.
- Net worth
- Neurogene Inc. has a market value (market cap) of $520.3M at the latest share price, and shareholders' equity of $354.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $90.4M.
- Cash flow
- In fiscal 2025 operations used $77.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Neurogene Inc.'s next report is expected around March 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Neurogene Inc. does
Neurogene Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NGNE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$90.4M | -$4.24 | -$78.4M |
| 2024 | $925K | -$75.1M | -$4.28 | -$71.4M |
| 2023 | $0 | -$36.3M | n/a | -$51.7M |
| 2022 | n/a | -$55.2M | -$1.04 | -$55.1M |
| 2021 | n/a | -$60.7M | -$1.10 | -$50.8M |
| 2020 | n/a | -$33.3M | -$0.64 | -$26.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Neurogene Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- August 11, 2026
- July 2, 2026
- June 29, 2026
Insider trades
What the people running Neurogene Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 22, 2026 | McMinn RachelChief Executive Officer, Director | Exercised options | 756 | $19.1K |
| July 7, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 4,200 | $151.8K |
| July 6, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 600 | $21.6K |
| July 2, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 2,531 | $87.5K |
| July 2, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 1,530 | $53.9K |
| July 1, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 739 | $25.2K |
| May 6, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 4,800 | $144.4K |
| May 6, 2026 | Cvijic Christine MikailPresident and CFO, Director | Soldpre-planned (10b5-1) | 4,800 | $155.7K |
Who owns NGNE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Samsara BioCapital, L.P.13G, passive with 2 related filers | 11.6% | November 27, 2024 |
| Jennison Associates LLC13G, passive | 11.1% | October 6, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 9.99% | February 14, 2025 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 9.9% | November 14, 2025 |
| Redmile Group, LLC13G, passive with 2 related filers | 9.9% | August 14, 2026 |
| Casdin Capital, LLC13G, passive with 3 related filers | 8.7% | February 14, 2025 |
| Julian C. Baker13G, passive with 3 related filers | 7% | August 14, 2025 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 5.18% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 112 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Samsara Biocapital, LLC | 1,717,127 | 0 |
| Casdin Capital, LLC | 1,545,361 | +125,000 |
| Redmile Group, LLC | 1,412,199 | -47,400 |
| Rtw Investments, LP | 1,362,456 | 0 |
| EcoR1 Capital, LLC | 1,271,342 | 0 |
| BlackRock, Inc. | 1,057,983 | +52,913 |
| Baker Bros. Advisors LP | 991,691 | 0 |
| Balyasny Asset Management L.P. | 818,706 | +100,317 |
| Trails Edge Capital Partners, LP | 714,885 | -67,902 |
| Toronto Dominion Bank | 681,337 | 0 |
| Vanguard Capital Management LLC | 536,525 | +21,798 |
| Jennison Associates LLC | 518,582 | -9,103 |
| Citadel Advisors LLC | 408,982 | +21,951 |
| Great Point Partners LLC | 352,180 | -147,820 |
| ArrowMark Colorado Holdings LLC | 342,453 | -182,343 |
| Fmr LLC | 295,561 | -87,086 |
| Geode Capital Management, LLC | 293,182 | +14,179 |
| State Street Corp | 224,322 | -88,683 |
| Franklin Resources Inc | 204,280 | new |
| Morgan Stanley | 191,724 | -93,515 |
Insiders
4 insiders reported holding 1,472,072 shares in total, about $38.3M at the last price.
| Holder | Shares |
|---|---|
| McMinn RachelChief Executive Officer, Director | 1,345,063 |
| Cvijic Christine MikailPresident and CFO, Director | 84,040 |
| Cobb StuartChief Scientific Officer | 30,497 |
| Jordan JulieChief Medical Officer | 12,472 |
Questions about NGNE
What does Neurogene Inc. do?
Neurogene Inc. is a company in the Health care sector, listed on NASDAQ as NGNE. Its shares trade on NASDAQ under the ticker NGNE.
What is Neurogene Inc.'s net worth?
Neurogene Inc. has a market value (market cap) of $520.3M at the latest share price, and shareholders' equity of $354.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Neurogene Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $119.2M.
When did Neurogene Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Neurogene Inc.'s next earnings report?
Neurogene Inc.'s next report is expected around March 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NGNE with
Follow NGNE
Get an email when Neurogene Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Neurogene Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.